This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Myeloid leukaemia골수성 백혈병 (골수성백혈병)

A. Classification codesICD-10: C92 | C92.0 Acute myeloid leukemia (AML) | C92.1 Chronic myeloid leukemia (CML), BCR-ABL positive | C92.2 Atypical chronic myeloid leukemia | C92.3 Myeloid sarcoma | C92.4 Acute promyelocytic leukemia (APL) | C92.5 Acute myelomonocytic leukemia | C92.6 AML with acute fibroblastic change | C92.9 AML, unspecified | Special Copayment Reduction V193 (copayment 5%, for 5 years from the registration date)
B. SynonymsAcute myeloid leukemia (AML), acute nonlymphocytic leukemia (ANLL), chronic myeloid leukemia (CML), Philadelphia chromosome-positive CML, acute promyelocytic leukemia (APL), acute myeloblastic leukemia, juvenile chronic myeloid leukemia (juvenile CML)
C. Adult onsetVery high — AML accounts for over 80% of adult acute leukemia; CML occurs at any age but predominates in adults in their 40s-60s; APL often has onset in middle age (30s-40s)
Contents 1. History · 2. Causes · 3. Genetics · 4. Epidemiology · 5. Pathophysiology · 6. Symptoms · 7. Signs · 8. Screening · 9. Diagnosis · 10. Treatment · 11. Prognosis · 12. Prevention · 13. References

1. History

There are two landmark events in the history of myeloid leukemia. One is the discovery of the Philadelphia chromosome, and the other is the development of imatinib. In 1960, Peter Nowell and David Hungerford discovered an abnormally small chromosome 22 in patients with chronic myeloid leukemia (CML) and named it the 'Philadelphia chromosome (Ph)' after Philadelphia, where their laboratory was located. This was the first case of a specific chromosomal abnormality found in a human cancer and became the starting point of tumor cytogenetics.

In 1973, Janet Rowley showed that the Ph chromosome is a reciprocal translocation between chromosomes 9 and 22 [t(9;22)], and in 1985 the BCR-ABL1 fusion gene was confirmed as the product of this translocation. In 2001, the BCR-ABL tyrosine kinase inhibitor imatinib (Gleevec), developed under the leadership of Brian Druker of Novartis, received FDA approval, which is regarded as a revolution in molecular targeted therapy. In CML, imatinib dramatically improved median survival from the previous 4-6 years to a level similar to that of the general population.

In the field of AML (acute myeloid leukemia), '7+3' chemotherapy (cytarabine for 7 days + daunorubicin for 3 days) was established as the standard induction regimen in the 1970s and remained the standard for decades thereafter. Since the 2000s, advances in molecular diagnostics have identified various prognostic markers such as FLT3, NPM1, and IDH1/2, and since 2017, the successive approvals of midostaurin (FLT3 inhibitor), enasidenib (IDH2 inhibitor), ivosidenib (IDH1 inhibitor), and, in 2018, venetoclax (BCL-2 inhibitor) in combination with azacitidine opened a new era of AML treatment. In APL (acute promyelocytic leukemia), the remarkable result of a 5-year survival rate above 90% was achieved in the 1990s with the combination of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO).

2. Causes

The causes of myeloid leukemia differ somewhat by type. Ionizing radiation is the best-established risk factor; the risk of AML and CML increases significantly in cancer patients who received radiation therapy, atomic bomb survivors, and radiation workers. After a latency period of 5-10 years following exposure, mainly acute myeloid leukemia develops.

Chemicals: benzene is the most important chemical risk factor for AML, increasing the incidence of AML several-fold with long-term, high-concentration exposure. Occupational exposure occurs in workers in the petrochemical industry, shoe manufacturing, and painting. Prior chemotherapy: AML develops 5-10 years after treatment with alkylating agents (cyclophosphamide, chlorambucil, melphalan) (alkylating agent-related AML, with frequent monosomal/complex karyotype and TP53 mutations), and 1-3 years after treatment with topoisomerase II inhibitors (etoposide, doxorubicin) (frequent 11q23 MLL rearrangement). This is called therapy-related AML (t-AML).

Antecedent hematologic disorders: myelodysplastic syndrome (MDS) progresses to AML in about 30%, which is called secondary AML (sAML). Myeloproliferative neoplasms such as polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) also carry a risk of acute transformation (blast phase). Hereditary disorders: genetic predispositions such as Fanconi anemia, Down syndrome, Bloom syndrome, Li-Fraumeni syndrome, germline CEBPA mutation, and germline RUNX1 mutation increase the risk of AML. In CML, no clear environmental risk factor other than radiation exposure has been identified.

3. Genetics

The genomic classification of myeloid leukemia is prognostically stratified based on the ELN 2022 (European LeukemiaNet 2022) AML classification.

Major genomic abnormalities in AML and ELN 2022 risk classification

Risk groupMajor genomic abnormalities5-year OS (approximate)
Favorablet(8;21) RUNX1-RUNX1T1, inv(16)/t(16;16) CBFB-MYH11, t(15;17) PML-RARA (APL), NPM1 mutation (without FLT3-ITD), CEBPA bZIP mutation60-70%
IntermediateFLT3-ITD, normal karyotype/other, t(9;11) KMT2A-MLLT340-50%
AdverseTP53 mutation, RUNX1 mutation, ASXL1 mutation, BCOR mutation, EZH2 mutation, SF3B1, U2AF1, SRSF2, ZRSR2 mutations, complex karyotype (≥3 abnormalities), monosomal karyotype, inv(3)/t(3;3), t(6;9), t(v;11q23.3) KMT2A rearrangement (excluding t(9;11)), t(9;22)10-20%

Key mutations: FLT3-ITD (FMS-like tyrosine kinase 3 internal tandem duplication) occurs in 25-30% of AML and is the target of midostaurin, gilteritinib, and quizartinib. NPM1 mutation (30-35% of AML, favorable prognosis when isolated) causes cytoplasmic dislocation of the nucleolar protein NPM1. IDH1/IDH2 mutations (6-8% of AML each) cause 2-hydroxyglutarate production → epigenetic changes → impaired differentiation. Targeted therapy is possible with ivosidenib (IDH1) and enasidenib/ivosidenib (IDH2). DNMT3A/TET2/ASXL1 mutations are initiating mutations of 'clonal hematopoiesis' and are associated with aging.

CML: the BCR-ABL1 fusion protein resulting from t(9;22)(q34;q11.2) is central. BCR-ABL1 is a constitutively activated tyrosine kinase that activates the RAS-MAPK, PI3K-AKT, and STAT5 pathways, promoting cell proliferation and survival and inhibiting apoptosis. The main mechanism of TKI resistance is ABL1 kinase domain mutation; T315I (gatekeeper mutation) is resistant to 1st- and 2nd-generation TKIs and is treated with ponatinib or asciminib (STAMP inhibitor).

4. General epidemiology

AML is the most common acute leukemia in adults, accounting for over 80% of all acute leukemias. About 200,000-250,000 people are newly diagnosed worldwide each year, with an incidence of 3-4 per 100,000 population. Incidence rises sharply with age, reaching 17 per 100,000 at age 65 and older. In Korea, AML has the highest incidence among hematologic cancers, and according to National Cancer Center statistics, about 1,200-1,500 people are diagnosed with AML each year. It is slightly more common in men (M:F ≈ 1.4:1), and the median age at diagnosis is around 65.

CML accounts for about 15% of all leukemias, with a worldwide incidence of about 1.5-2 per 100,000 population. In Korea, about 600-700 people are diagnosed with CML each year, and since the introduction of imatinib the number of patients managed long-term with TKIs has been steadily increasing. APL is a subtype of AML accounting for 5-15% of all AML and, unusually, has a peak onset in middle age (35-45 years). Early death due to the coagulopathy peculiar to APL was a problem, but in the ATRA+ATO era the early mortality rate has decreased greatly. Secondary AML (t-AML) accounts for 10-20% of all AML and belongs to the poor-prognosis group.

5. Pathophysiology

The pathogenesis of AML is explained by a 'two-hit' or 'multi-hit' model. The first hit is an initiating mutation (DNMT3A, TET2, ASXL1) causing clonal hematopoiesis (CH), which accumulates even during normal aging. The second hit is a cooperating mutation (FLT3-ITD, NPM1, KIT, CEBPA, etc.) that causes impaired differentiation, completing the transformation to acute leukemia.

At the molecular level, differentiation block is the key mechanism. The RUNX1-RUNX1T1 fusion protein (t(8;21)) and CBFB-MYH11 (inv16) inhibit the function of normal core-binding factor (CBF), blocking maturation of myeloid progenitors. PML-RARA (APL) inhibits retinoic acid receptor signaling, arresting differentiation at the promyelocyte stage. NPM1 mutation dislocates the nucleolar protein to the cytoplasm, disrupting transcription factor function. FLT3-ITD maintains proliferative signaling constitutively through constitutive activation of STAT5.

Pathogenesis of CML: the BCR-ABL1 fusion protein simultaneously activates the following pathways: RAS/RAF/MEK/ERK (proliferation), PI3K/AKT/mTOR (survival, anti-apoptosis), JAK2/STAT5 (anti-apoptosis, proliferation), NF-κB (survival). As a result, myeloid progenitors proliferate without limit, and mature but functionally abnormal myeloid cells are released excessively into the peripheral blood. Untreated, it progresses from chronic phase → accelerated phase → blast crisis, and additional genomic abnormalities accumulate in blast crisis.

6. Symptoms

The symptoms of AML arise from two sources: pancytopenia due to bone marrow failure and tissue destruction due to leukemic cell infiltration. Symptoms of bone marrow failure: fatigue, weakness, and pallor (anemia); fever, infection, and sepsis (neutropenia); petechiae, purpura, gum bleeding, epistaxis, and menorrhagia (thrombocytopenia). Symptoms of leukemic cell infiltration: bone pain, lymphadenopathy, splenomegaly and hepatomegaly, gingival hypertrophy (gingival infiltration, characteristic especially in monocytic AML), leukemia cutis (purple nodules), and rarely leukemic cell tumors (chloroma/myeloid sarcoma).

Symptoms specific to APL: a severe bleeding tendency due to disseminated intravascular coagulation (DIC) is characteristic. Severe bleeding without trauma (cerebral hemorrhage, pulmonary hemorrhage, gastrointestinal bleeding) is the main cause of early death. When APL is suspected, starting ATRA immediately is critical to preventing early death.

Symptoms of chronic-phase CML: progresses slowly, with fatigue, left upper quadrant discomfort (splenomegaly), weight loss, and sweating as the main initial symptoms. With hyperleukocytosis (leukostasis, WBC >100,000/μL), headache, dyspnea, visual changes, and priapism may occur. In blast crisis, an abrupt worsening of symptoms similar to AML or ALL occurs.

7. Signs

Signs of AML: on complete blood count, pancytopenia or leukocytosis (variable WBC, >100,000/μL in some). Blasts are identified on peripheral blood smear; Auer rods are a finding specific to AML and are especially abundant in APL (faggot cells). Marked elevation of serum LDH and uric acid. Abnormal coagulation tests (prolonged PT/APTT, decreased fibrinogen — DIC in APL). Liver and renal function abnormalities may accompany. Splenomegaly and hepatomegaly (physical examination), lymphadenopathy, gingival hypertrophy, skin lesions.

Signs of CML: neutrophilia in peripheral blood and a variety of myeloid cells at intermediate stages of maturation (myelocytes, metamyelocytes, basophils, eosinophils). Basophilia is a specific finding of CML. Thrombocytosis (>450,000/μL) is common. Giant spleen (palpable below the umbilicus). Bone marrow examination: hypercellular marrow, increased megakaryocytes. Ph chromosome or BCR-ABL1 confirmed by karyotyping or FISH. BCR-ABL1/ABL1 ratio measured by quantitative PCR (qPCR) (essential for monitoring treatment response).

8. Screening

There is no standard population screening for either AML or CML. Active testing is needed in the following situations.

Monitoring of high-risk groups: in cancer patients who previously received radiation or chemotherapy, perform a complete blood count at every follow-up visit, and in patients with MDS or myeloproliferative neoplasms, monitor for acute transformation with regular bone marrow examinations. In patients with confirmed clonal hematopoiesis (CHIP, clonal hematopoiesis of indeterminate potential) (especially carriers of TP53, DNMT3A, or TET2 mutations), complete blood counts 1-2 times a year and regular follow-up are recommended.

Monitoring of treatment response in CML: in CML patients on TKI therapy, quantitative BCR-ABL1 PCR (every 3 months) is central to assessing treatment response. ELN milestones: BCR-ABL1 ≤10% at 3 months, ≤1% at 6 months, ≤0.1% (MMR) at 12 months. If milestones are not met, a TKI switch or ABL1 kinase mutation analysis to identify the resistance mechanism is needed. Monthly PCR follow-up is mandatory when attempting treatment-free remission (TFR).

In patients with unexplained leukocytosis, splenomegaly, bone pain, or unexplained anemia and thrombocytopenia, immediately perform a complete blood count + peripheral blood smear + referral to a hematologist.

9. Diagnosis

Diagnosis of AML: follows the WHO 2022 and ICC (International Consensus Classification) 2022 criteria. The threshold is bone marrow blasts ≥20% (threshold not applicable for some genotypes), and when AML-defining genomic abnormalities [t(8;21), inv(16), t(15;17), NPM1 mutation, CEBPA bZIP mutation] are present, AML is diagnosed regardless of the blast percentage.

Essential tests: bone marrow aspiration and biopsy (morphology, iron stain), flow cytometry (immunophenotype, CD13/CD33/CD34/CD117/MPO/CD64/CD14, etc.), karyotype analysis (standard cytogenetics), FISH (CBF abnormalities, APL), molecular genetic NGS panel (FLT3-ITD/TKD, NPM1, CEBPA bZIP, IDH1, IDH2, TP53, DNMT3A, TET2, RUNX1, ASXL1, KIT, NRAS/KRAS). In APL, PML-RARA FISH or RT-PCR should be performed as the top priority and ATRA given immediately.

Diagnosis of CML: Ph positivity (karyotype) or positive BCR-ABL1 FISH/RT-PCR + determination of chronic/accelerated phase/blast crisis by peripheral blood and bone marrow examination. CML phases (WHO criteria): chronic phase (blasts <10%), accelerated phase (blasts 10-19%, other criteria), blast crisis (blasts ≥20%). Baseline BCR-ABL1 level measured by qRT-PCR (reference for later comparison of treatment response).

10. Treatment

Treatment of AML

Patients eligible for intensive chemotherapy (mainly under 60 with good performance status): the standard induction regimen is the 7+3 regimen (cytarabine 100-200 mg/m² for 7 days + daunorubicin or idarubicin for 3 days). In the favorable-risk group (CBF-AML), gemtuzumab ozogamicin is added. With FLT3 mutation, midostaurin or quizartinib is added. Consolidation after complete remission: high-dose cytarabine (HiDAC) for the favorable-risk group, and allogeneic hematopoietic stem cell transplantation (allo-HSCT) for the intermediate- and adverse-risk groups. APL: ATRA + ATO (arsenic trioxide) combination is the standard for newly diagnosed low/intermediate risk. In high risk (WBC ≥10,000/μL), ATRA + ATO + an anthracycline are added.

Patients ineligible for intensive chemotherapy (mainly age 75 or older or with comorbidities): the combination of venetoclax + azacitidine (Aza-Ven) has been established as standard since 2018. Overall survival improved 2-fold (median OS 14.7 months vs 9.6 months, VIALE-A trial). IDH1 mutation: ivosidenib ± azacitidine. IDH2 mutation: enasidenib. FLT3 mutation: gilteritinib (approved for relapsed/refractory disease). In relapsed/refractory AML: gilteritinib (FLT3+), ivosidenib (IDH1+), enasidenib (IDH2+), glasdegib + low-dose cytarabine, allogeneic HSCT.

Treatment of CML

First-line treatment of chronic-phase CML is imatinib (400mg/day) or a 2nd-generation TKI, dasatinib, nilotinib, or bosutinib. 2nd-generation TKIs induce faster and deeper responses than imatinib, but an OS advantage is unclear. The T315I mutation requires ponatinib or asciminib. The treatment goal is deep molecular response (DMR, MR4.0-4.5); once this is achieved and maintained for 2 years or more, treatment-free remission (TFR) can be attempted. In accelerated phase and blast crisis, TKI + intensive chemotherapy + allogeneic HSCT is considered. Under Korean National Health Insurance, imatinib is covered as first line, and 2nd-generation TKIs are covered after imatinib failure or in certain high-risk patients.

11. Prognosis

Prognosis of AML: the overall 5-year survival rate is about 30%, but it differs greatly by ELN risk group. In the favorable-risk group, such as CBF-AML (t(8;21), inv16), 5-year OS reaches 60-70%, while in the adverse-risk group, such as complex karyotype and TP53 mutation, 5-year OS is only 5-15%. APL is the AML subtype with the highest cure rate, with 5-year OS above 90% in the ATRA+ATO era. In AML at age 65 or older, 5-year OS is very low at 10-15%, but it is improving with the venetoclax + azacitidine regimen.

Prognosis of CML: from a median OS of 4-6 years in the pre-imatinib era, it has improved dramatically in the TKI era to a 10-year OS of 80-90% or more. The 10-year OS of chronic-phase CML patients treated with imatinib is similar to that of the general population (>85% for the Sokal low-risk group). Sokal, EURO, EUTOS, and ELTS scores are used to predict prognosis in CML. When resistance due to the ABL1 kinase T315I mutation emerges, it can mostly be overcome with ponatinib, but the prognosis is poor with additional compound mutations. Treatment-free remission (TFR) is successfully maintained in about 50% of patients who achieved deep molecular response.

12. Prevention

For primary prevention of myeloid leukemia, it is important to minimize known risk factors. Radiation safety management: compliance with safety standards for occupational radiation exposure, rational use of medical radiation, minimizing unnecessary CT scans. Blocking exposure to hazardous chemicals such as benzene: strengthening workplace environmental standards, wearing personal protective equipment, and early detection of abnormalities through regular health checkups (including blood tests).

Monitoring after prior anticancer treatment: early detection of therapy-related MDS or AML through regular complete blood counts in patients who received alkylating agents or topoisomerase II inhibitors. Hereditary high-risk groups: pre-onset monitoring through regular blood tests and genetic counseling in families carrying germline mutations such as CEBPA, RUNX1, and DDX41. Carriers of clonal hematopoiesis (CHIP) need follow-up for both cardiovascular risk and hematologic cancer risk. To prevent CML accelerated phase and blast crisis, maintain adherence to TKI therapy and detect emerging resistance early through regular PCR monitoring.


13. References

  1. Döhner H, et al. Diagnosis and management of AML in adults: 2022 ELN recommendations. Blood. 2022;140(12):1345-1377.
  2. Döhner H, et al. Acute myeloid leukaemia. Nat Rev Dis Primers. 2021;7(1):15.
  3. DiNardo CD, et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med. 2020;383(7):617-629.
  4. Hochhaus A, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966-984.
  5. Sanz MA, et al. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood. 2019;133(15):1630-1643.
  6. Stone RM, et al. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N Engl J Med. 2017;377(5):454-464.
  7. Korean Society of Hematology. Clinical practice guidelines for acute myeloid leukemia and chronic myeloid leukemia 2023. Seoul: Korean Society of Hematology.
  8. National Cancer Center. Cancer Registration Statistics in Korea, 2022. Ministry of Health and Welfare (MOHW) and National Cancer Center. 2024.
  9. Druker BJ, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408-2417.
  10. Kim Dong-wook. Treatment of acute myeloid leukemia. Journal of the Korean Medical Association. 2023;66(4):234-244.